doi: 10.1016/s0140-6736(76)91416-1.
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy
- PMID: 55599
- DOI: 10.1016/s0140-6736(76)91416-1
Item in Clipboard
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy
Lancet.
.
Abstract
Fluctuations in performance in patients with Parkinson's disease on chronic levodopa therapy (the "on-off" effect) are due to several factors. The increasing severity during treatment of early morning akinesia, "freezing" episodes, and end-of-dose deterioration are probably due to progression of the underlying disease. Peak-dose dyskinesia and peak-dose akinesia are due to levodopa over dosage. "Yo-yo-ing", which is the severest form of such fluctuation in mobility and dyskinesias, may represent the sum of these disorders.
Similar articles
-
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.Neurology. 1993 Aug;43(8):1545-50. doi: 10.1212/wnl.43.8.1545. Neurology. 1993. PMID: 8351009
-
Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.Mov Disord. 1989;4(3):195-201. doi: 10.1002/mds.870040301. Mov Disord. 1989. PMID: 2779590
-
Variations in the "on-off" effect.Adv Neurol. 1974;5:397-9. Adv Neurol. 1974. PMID: 4440587 No abstract available.
-
Continuous dopaminergic stimulation for Parkinson's disease: facts and fancy.Funct Neurol. 1988 Oct-Dec;3(4):413-27. Funct Neurol. 1988. PMID: 3072277 Review. No abstract available.
-
Rapid treatment of "wearing off" in Parkinson's disease.Neurology. 2004 Mar 23;62(6 Suppl 4):S27-31. doi: 10.1212/wnl.62.6_suppl_4.s27. Neurology. 2004. PMID: 15037669 Review.
Cited by
-
Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.J Neural Transm. 1985;62(1-2):1-52. doi: 10.1007/BF01260414. J Neural Transm. 1985. PMID: 3894582 Review.
-
Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein.Bioorg Med Chem. 2023 Jan 15;78:117131. doi: 10.1016/j.bmc.2022.117131. Epub 2022 Dec 16. Bioorg Med Chem. 2023. PMID: 36571976 Free PMC article.
-
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes.Health Psychol Res. 2022 Jun 28;10(3):36074. doi: 10.52965/001c.36074. eCollection 2022. Health Psychol Res. 2022. PMID: 35774903 Free PMC article.
-
Severity of Caregiver Stress in Relation to Severity of Disease in Persons with Parkinson's.Cureus. 2019 Apr 1;11(4):e4358. doi: 10.7759/cureus.4358. Cureus. 2019. PMID: 31192063 Free PMC article.
-
High-Resolution Motor State Detection in Parkinson's Disease Using Convolutional Neural Networks.Sci Rep. 2020 Apr 3;10(1):5860. doi: 10.1038/s41598-020-61789-3. Sci Rep. 2020. PMID: 32246097 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
